Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.
Immunofoco a company dedicated to developing cell therapy products for solid tumors announced a significant milestone that following the approval by the CDE in China for the clinical trial application of IMC an EpCAMtargeting autologous CART cell pro...
Servier a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves today announced the FDA filing acceptance and priority review for a New Drug Application
Everest Medicines partner Pfizer Inc announced that the European Commission has granted marketing authorization for VELSIPITY in the European Union to treat patients years of age and older with
Matinas BioPharma a clinicalstage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal platform delivery technology announces alignment
Everest Medicines licensing partner Venatorx Pharmaceuticals announced that The New England Journal of Medicine published the results of the CERTAIN Phase clinical study of the investigational agent
Hox Therapeutics Ltd a private biotechnology company developing highly targeted cancer therapies and Vernalis Ltd a fully owned subsidiary of HitGen Inc are pleased to announce a collaboration
Neurophth Therapeutics Inc announced today that the last patient has been enrolled in Phase III clinical trial of Opvika for the treatment of Leber hereditary optic neuropathy caused by ND mutation
Biocytogen Pharmaceutical Technology Co Ltd today announced an agreement with Gilead Sciences Antibody evaluation and selection protocol The agreement authorizes Gilead to use Biocytogens fully human antibody library for a broad range of drug targets...
Everest Medicines a biopharmaceutical company focused on the development manufacturing and commercialization of innovative medicines and vaccines announced today that it will terminate the
CASI Pharmaceuticals Inc a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products proudly announced the administration of the first dose of FOLOTYN
